Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
| ▸ | BRS3 | P32247 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 1/20 | 0.57 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618054 | 1.00 | KMT2A (0.64) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL18625066 | 0.91 | IL1RN (0.55) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL16616751 | 0.90 | KMT2A (0.70) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL16616752 | 0.90 | KMT2A (0.70) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL6355051 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL29138492 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL16626132 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL6362124 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL21937714 | 0.89 | MAPT (0.61) | KMT2AMEN1HCRTR1MAPTTP53 | |
| SCHEMBL30127739 | 0.89 | MAPT (0.61) | KMT2AMEN1HCRTR1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593144-B2 | FPR1 antagonist derivatives and use thereof | CHANG GUNG UNIVERSITY (TW) | 2017-03-14 | — | — | US | disclosed |
| US-9593144-B2 | FPR1 antagonist derivatives and use thereof | CHANG GUNG UNIVERSITY (TW) | 2017-03-14 | — | — | US | disclosed |
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-10-29 | — | — | US | disclosed |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | KMT2A 4039/4885MEN1 1728/4885HCRTR1 91/4885 |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | KMT2A 4039/4885MEN1 1728/4885HCRTR1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.